System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Igor Bondarenko

Oncology — Dnipropetrovsk State Medical Academy, Ukraine

LeadR Profile

Igor Bondarenko Dnipropetrovsk State Medical Academy Ukraine
2 144 ScienceLeadR Reputation 2144

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pulmonology - Public Health - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2000 - 2026
Source: PubMed

Dnipropetrovsk State Medical Academy

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 395

Citations

Citations: 65 673 1st author: 15 Last author: 12 Unique author: 0

Main journals

J Clin Oncol 102
Ann Oncol 70
Cancer Res 25
N Engl J Med 25
J Thorac Oncol 18

Best Journals

Ann Oncol 33
J Clin Oncol 32
N Engl J Med 22

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Continued Cemiplimab Beyond Progression With Addition of Chemotherapy in Patients With Advanced NSCLC With PD-L1 Expression of 50% or Higher: 5-Year Follow-Up From EMPOWER-Lung 1.
confidence intervals, lung, safety, carcinoma, non-small-cell lung, drug therapy, drug-related side effects and adverse reactions, histology, therapeutics, chemotherapy		JTO Clin Res Rep20260
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.
cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma		J Clin Oncol Top journal20262
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial.
cells, lung, safety, neoplasms, drug therapy, lung neoplasms, small cell lung carcinoma, therapeutics, chemotherapy		JAMA Oncol20260
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.
progression-free survival, neoplasms, adenocarcinoma, drug therapy, drug-related side effects and adverse reactions, therapeutics, trastuzumab, chemotherapy		N Engl J Med Top journal20260
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial.
cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, therapeutics, chemotherapy		Lung Cancer20260

Clinical Studies 87

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 69
Phase 2 11
Phase 1/Phase 2 4
Phase 1 2
N/A 1

By status:

Completed 65
Active not recruiting 13
Terminated 9

By type:

Interventional 86
Observational 1

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 0
multicentric5to9 1
multicentricup10 80

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2 positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147 — cells, lewy bodies, stomach, parkinson disease, esophagus, neoplasms, adenocarcinoma, drug therapy, oxaliplatin, fluorouracil, immunotherapy, receptors, death domain, esophageal neoplasms, capecitabine, cell death, stomach neoplasms, trastuzumab, chemotherapy		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS